{"id":6654,"date":"2024-11-21T14:26:26","date_gmt":"2024-11-21T13:26:26","guid":{"rendered":"https:\/\/beigen.vipdev.lndo.site\/us\/?post_type=publication&p=6654"},"modified":"2025-04-28T21:46:54","modified_gmt":"2025-04-28T19:46:54","slug":"clinical-dose-rationale-of-tislelizumab-in-patients-with-solid-or-hematological-advanced-tumors","status":"publish","type":"publication","link":"https:\/\/beonemedaffairs.com\/us\/publication\/clinical-dose-rationale-of-tislelizumab-in-patients-with-solid-or-hematological-advanced-tumors\/","title":{"rendered":"Clinical dose rationale of tislelizumab in patients with solid or hematological advanced tumors\u00a0"},"content":{"rendered":"","protected":false},"template":"","post-tag":[],"class_list":["post-6654","publication","type-publication","status-publish","hentry","disease_state-advanced-solid-tumors","disease_state-classical-hodgkins-lymphoma","disease_state-esophageal-squamous-cell-carcinoma","disease_state-gastric-cancer","disease_state-hepatocellular-carcinoma","disease_state-melanoma","disease_state-non-small-cell-lung-cancer","disease_state-ovarian-cancer","disease_state-sarcoma","disease_state-triple-negative-breast-cancer","molecule-tislelizumab"],"acf":[],"_links":{"self":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/publication\/6654","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/publication"}],"about":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/types\/publication"}],"wp:attachment":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/media?parent=6654"}],"wp:term":[{"taxonomy":"post-tag","embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag?post=6654"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}